KRAS and cancer: Considering the high prevalence of KRAS point mutations in human tumors and the responsive role of REGγ in KRAS oncogenic signaling, inhibitors targeting the REGγ-proteasome complex could enhance antitumor activity and represent a broadly applicable approach in cancer therapy.